The Skimune^® platform (Skimune^®Cosm; Skimune^®Chem; Skimune^®Mab) are unique non-artificial human in vitro skin tests

The Skimune^® platform predicts hypersensitivity responses to pharmaceuticals including small molecule pharmaceuticals and monoclonal antibodies, chemicals and cosmetics

Skimune^® provides a pre-clinical predictive readout of skin damage which correlates with screening assays; cytokine release syndrome (CRS) and T cell proliferation responses

Skimune^®Mab is the only commercially available test for predicting adverse reactions to monoclonal antibodies, biobetters, biosimilar and antibody drug conjugates

The Skimune^® platform tests are used in dose response and efficacy studies for immunomodulatory drugs prior to Phase One clinical trials